Evolocumab Approved to Prevent Heart Attack, Stroke

The FDA recently issued a supplemental approval to evolocumab (Repatha) for the prevention of heart attacks, strokes, and coronary revascularizations in adult patients with established heart disease, according to a press release.
Evolocumab is the first PCSK9 inhibitor to receive this indication, Amgen reported.
"We are pleased that the FDA made the inclusion of our outcomes data a priority so that patients can benefit from Repatha's ability to reduce life-changing events of heart attacks and strokes," said Sean E. Harper, MD, executive vice president of Research and Development at Amgen. "Despite treatment with current best therapy, many patients are still at high risk for cardiovascular events. Physicians now have a new FDA-approved treatment option to prevent cardiovascular events by dramatically lowering LDL cholesterol with Repatha, especially for patients already on maximally-tolerated statin therapy who need further LDL cholesterol lowering."
In the FOURIER clinical trial, evolocumab demonstrated significant benefits for 27,564 patients with established cardiovascular disease, according to Amgen.
The researchers found that evolocumab lowered the risk of heart attack by 27%, the risk of stroke by 21%, and the risk of coronary revascularization by 22%, according to the release.
Evolocumab is also approved as a monotherapy or in addition to other lipid-lowering drugs to reduce low-density lipoprotein cholesterol among adults with primary hyperlipidemia as an adjunct to diet, according to Amgen.
Currently, Amgen helps patients gain access to financial assistance, insurance support, and injection training through their RepathaReady program. Patients may also be able to start therapy with evolocumab free of cost through the manufacturer, according to the release.
"In the US, every 40 seconds someone has a heart attack or stroke, and nearly 1 in 3 of these patients will have another event, leading to a societal cost that exceeds $600 billion annually. With this approval, it's now more important than ever that appropriate patients obtain access to Repatha in order to avoid preventable heart attacks and strokes," said Anthony C. Hooper, executive vice president of Global Commercial Operations at Amgen. “We will continue to work with payers to help ensure the patients who need Repatha the most are able to get this innovative medicine.”

For neurologists working in stroke care, Specialty Pharmacy Times' new sister site, NeurologyLive, serves as a resource for extensive clinical news, articles, videos, and newly released data and research.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Most Popular

Related Articles

Evolocumab (Repatha) consistently reduced low-density lipoprotein cholesterol in high-risk patients over time.
Emapalumab (Gamifant) is the first treatment specifically approved for primary hemophagocytic lymphohistiocytosis, a rare and life-threatening immune disease.
Top news of the day from across the health care landscape
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.